Morgan Stanley downgrades Novo Nordisk to Underweight
Morgan Stanley cut its rating on Novo Nordisk, citing ongoing concern over semaglutide’s loss of exclusivity overhang. Shares were down more than 1% premarket.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.